로딩 중…
StockDiggingStockDigging

ANI Pharmaceuticals, Inc.

ANIP· NASDAQ
$79.50-1.27%
2026-06-18

Price Chart

ANI Pharmaceuticals, Inc.+22.95%

Financials

※ FY = Fiscal Year

Investment Metrics(as of 2026-06-18)

MetricValue
Size
Market Cap$1.81B
Revenue$924M
Net Income$90M
Total Assets$1.42B
Net Assets$562M
Employees970
Value
P/E20.16x
P/B3.21x
PEG0.23x
P/S1.96x
EV/EBITDA7.70x
FCF Yield9.16%
Profitability
ROE15.95%
ROA6.31%
Op. Margin13.38%
Revenue Growth20.46%
Earnings Growth88.07%
Financial Health
Debt Ratio152.88%
Total Debt$328M
FCF$166M
Cash$311M
Current Ratio3.12x
Net Debt/EBITDA0.07x
Performance
1Y Return22.95%
1M Return-1.02%
From 52W High-20.10%
1Y MDD-28.66%
Trading
Volume186,863 shares
Trading Value$15M
Per Share
EPS$3.78
BPS$26.96

Company Info

CEO Mr. Nikhil Lalwani
Employees 970
HQ Baudette, United States

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.